Affiliation:
1. Department of Pathology, Nuremberg Clinic, Paracelsus Medical University, 90419 Nuremberg, Germany
Abstract
Thymic epithelial tumors (TETs) are characterized by their extreme rarity and variable clinical presentation, with the inadequacy of the use of histological classification alone to distinguish biologically indolent from aggressive cases. The utilization of Next Generation Sequencing (NGS) to unravel the intricate genetic landscape of TETs could offer us a comprehensive understanding that is crucial for precise diagnoses, prognoses, and potential therapeutic strategies. Despite the low tumor mutational burden of TETS, NGS allows for exploration of specific genetic signatures contributing to TET onset and progression. Thymomas exhibit a limited mutational load, with prevalent GTF2I and HRAS mutations. On the other hand, thymic carcinomas (TCs) exhibit an elevated mutational burden, marked by frequent mutations in TP53 and genes associated with epigenetic regulation. Moreover, signaling pathway analyses highlight dysregulation in crucial cellular functions and pathways. Targeted therapies, and ongoing clinical trials show promising results, addressing challenges rooted in the scarcity of actionable mutations and limited genomic understanding. International collaborations and data-sharing initiatives are crucial for breakthroughs in TETs research.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference83 articles.
1. (2023, October 24). Thymoma Workup. Available online: https://emedicine.medscape.com/article/193809-overview?form=fpf.
2. (2023, October 24). Thymoma (Thymic Carcinoma). Available online: https://my.clevelandclinic.org/health/diseases/6196-thymoma-and-thymic-carcinoma.
3. (2023, October 24). Thymoma and Thymic Carcinoma Treatment (PDQ®), Available online: https://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq.
4. Petrini, I., Rajan, A., Pham, T., Voeller, D., Davis, S., Gao, J., Wang, Y., and Giaccone, G. (2013). Whole Genome and Transcriptome Sequencing of a B3 Thymoma. PLoS ONE, 8.
5. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients;Remon;Clin. Lung Cancer,2022